Review ArticleReview Article
Open Access

Tumefactive demyelinating lesions: A literature review of recent findings

Yaser M. Al Malik
Neurosciences Journal July 2024, 29 (3) 153-160; DOI: https://doi.org/10.17712/nsj.2024.3.20230111

References

  1. 1.↵
    1. Algahtani H,
    2. Shirah B,
    3. Alassiri A
    . Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord 2017; 14: 72–79.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Höftberger R,
    2. Lassmann H
    . Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neurol 2017: 145: 263-283.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Thompson AJ,
    2. Banwell BL,
    3. Barkhof F,
    4. Carroll WM,
    5. Coetzee T,
    6. Comi G, et al.
    Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162-173.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Tremblay MA,
    2. Villanueva-Meyer JE,
    3. Cha S,
    4. Tihan T,
    5. Gelfand JM
    . Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions. J Neurol Sci 2017; 381: 83-87.
    OpenUrlCrossRef
  5. 5.↵
    Neuroimmunology Group of Neurology Branch of Chinese Medical Association, Neuroimmunology Committee of Chinese Society for Immunology, Immunology Society of Chinese Stroke Association. Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System. Chin Med J (Engl) 2017; 130: 1838-1850.
    OpenUrl
  6. 6.↵
    1. Brod SA,
    2. Lindsey JW,
    3. Nelson F
    . Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments. Mult Scler J - Exp Transl Clin 2019; 5: 2055217319855755.
    OpenUrl
  7. 7.↵
    1. Jain RS,
    2. Khan I,
    3. Kandelwal K,
    4. Desai T
    . Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features. Clin Neurol Neurosurg 2017; 162: 91-94.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Balloy G,
    2. Pelletier J,
    3. Suchet L,
    4. Lebrun C,
    5. Cohen M,
    6. Vermersch P, et al.
    Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. J Neurol 2018; 265: 2251–2259.
    OpenUrl
  9. 9.↵
    1. Suh CH,
    2. Kim HS,
    3. Jung SC,
    4. Choi CG,
    5. Kim SJ
    . MRI findings in tumefactive demyelinating lesions: A systematic review and meta-analysis. AJNR Am J Neuroradiol 2018; 39: 1643-1649.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. van Langelaar J,
    2. Rijvers L,
    3. Smolders J,
    4. Van Luijn Marvin M
    . B and T cells driving multiple sclerosis: Identity, mechanisms and potential triggers. Front Immunol 2020; 11: 760.
    OpenUrl
  11. 11.↵
    1. Parnell GP,
    2. Booth DR
    . The multiple sclerosis (MS) genetic risk factors indicate both acquired and innate immune cell subsets contribute to ms pathogenesis and identify novel therapeutic opportunities. Front Immunol 2017; 8: 425.
    OpenUrl
  12. 12.↵
    1. De Silvestri A,
    2. Capittini C,
    3. Mallucci G,
    4. Bergamaschi R,
    5. Rebuffi C,
    6. Pasi A, et al.
    The involvement of HLA class II alleles in multiple sclerosis: A systematic review with meta-analysis. Dis Markers 2019; 2019: 1409069.
    OpenUrl
  13. 13.↵
    1. Z Ghali MG
    . Tumefactive acute disseminated encephalomyelitis. Neurol India 2020; 68: 35-41.
    OpenUrlPubMed
  14. 14.↵
    1. Zabad RK,
    2. Stewart R,
    3. Healey KM
    . Pattern recognition of the multiple sclerosis syndrome. Brain Sci 2017; 7: 138.
    OpenUrl
  15. 15.↵
    1. Hardy TA,
    2. Corboy JR,
    3. Weinshenker BG
    . Baló concentric sclerosis evolving from apparent tumefactive demyelination. Neurology 2017; 88: 2150–2152.
    OpenUrl
  16. 16.↵
    1. Avila M,
    2. Bansal A,
    3. Culberson J,
    4. Peiris AN
    . The role of sex hormones in multiple sclerosis. Eur Neurol 2018; 80: 93-99.
    OpenUrl
  17. 17.↵
    1. Jeung L,
    2. Smits LMG,
    3. Hoogervorst ELJ,
    4. van Oosten BW
    , M Frequin ST. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod. Mult Scler Relat Disord 2020; 40: 101978.
    OpenUrl
  18. 18.↵
    1. Sánchez P,
    2. Meca-Lallana V,
    3. Barbosa A,
    4. Manzanares R,
    5. Palmí I,
    6. Vivancos J
    . Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature. J Neurol Sci 2017; 381: 32-38.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Ashtari F,
    2. Sahraian MA,
    3. Oustad M,
    4. Nilipour Y
    . Tumefactive rebound of multiple sclerosis after the short-term cessation of fingolimod: A case report. Mult Scler Relat Disord 2019; 39: 101883.
    OpenUrlPubMed
  20. 20.↵
    1. Sato K,
    2. Niino M,
    3. Kawashima A,
    4. Yamada M,
    5. Miyazaki Y,
    6. Fukazawa T
    . Disease exacerbation after the cessation of fingolimod treatment in Japanese patients with multiple sclerosis. Intern Med 2018; 57: 2647-2655.
    OpenUrl
  21. 21.
    1. Okada K,
    2. Hashimoto T,
    3. Kobata M,
    4. Kakeda S,
    5. Takahashi T,
    6. Hirato J
    . Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod. Neurol Neuroimmunol Neuroinflamm 2018; 5: e484.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Lapucci C,
    2. Baroncini D,
    3. Cellerino M,
    4. Boffa G,
    5. Callegari I,
    6. Pardini M, et al.
    Different MRI patterns in MS worsening after stopping fingolimod. Neurol Neuroimmunol Neuroinflammation 2019; 6: e566.
    OpenUrl
  23. 23.↵
    1. Sánchez P,
    2. Meca-Lallana V,
    3. Vivancos J
    . Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases. Mult Scler Relat Disord 2018; 25: 95-98.
    OpenUrlPubMed
  24. 24.↵
    1. Yoshii F,
    2. Moriya Y,
    3. Ohnuki T,
    4. Ryo M,
    5. Takahashi W
    . Neurological safety of fingolimod: An updated review. Clin Exp Neuroimmunol 2017; 8: 233-243.
    OpenUrl
  25. 25.↵
    MedSafe Pharmacovigilence Team. Fingolimod and Tumefactive Lesions [Internet]. Medicines Adverse Reactions Committee, Govn. of New Zealand; 2019. Available from: https://www.medsafe.govt.nz/committees/marc/reports/177-3.2.1%20Fingolimod%20and%20tumefactive%20lesions_Redacted.pdf
  26. 26.↵
    1. Moghadasi AN,
    2. Baghbanian SM
    . Tumefactive demyelinating lesions in a patient with multiple sclerosis receiving natalizumab. Acta Neurol Belg 2019; 119: 137-139.
    OpenUrl
  27. 27.↵
    1. Barton J,
    2. Hardy TA,
    3. Riminton S,
    4. Reddel SW,
    5. Barnett Y,
    6. Coles A, et al.
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology 2017; 88: 1004.
    OpenUrl
  28. 28.↵
    1. Moreira Ferreira VF,
    2. Meredith D,
    3. Stankiewicz JM
    . Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab. Neurol Neuroimmunol Neuroinflamm 2019; 6: e589.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Pessini LM,
    2. Kremer S,
    3. Auger C,
    4. Castilló J,
    5. Pottecher J,
    6. de Sèze J, et al.
    Tumefactive inflammatory leukoencephalopathy in cocaine users: Report of three cases. Mult Scler Relat Disord 2020; 38: 101496.
    OpenUrl
  30. 30.↵
    1. Mitsutake A,
    2. Sato T,
    3. Katsumata J,
    4. Kusunoki Nakamoto F,
    5. Seki T,
    6. Maekawa R, et al.
    Tumefactive multiple sclerosis which initially presented with brainstem encephalitis with a long-term follow-up. Mult Scler Relat Disord 2019; 32: 23-26.
    OpenUrl
  31. 31.↵
    1. Ekmekci O,
    2. Eraslan C
    . Silent tumefactive demyelinating lesions and radiologically isolated syndrome. Case Rep Neurol Med 2018; 2018: 8409247.
    OpenUrl
  32. 32.↵
    1. Hiremath SB,
    2. Muraleedharan A,
    3. Kumar S,
    4. Nagesh C,
    5. Kesavadas C,
    6. Abraham M, et al.
    Combining diffusion tensor metrics and DSC perfusion imaging: Can it improve the diagnostic accuracy in differentiating tumefactive demyelination from high-grade glioma? AJNR Am J Neuroradiol 2017; 38: 685-690.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Blasel S,
    2. Pfeilschifter W,
    3. Jansen V,
    4. Mueller K,
    5. Zanella F,
    6. Hattingen E
    . Metabolism and regional cerebral blood volume in autoimmune inflammatory demyelinating lesions mimicking malignant gliomas. J Neurol 2011; 258: 113-122.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Tae W-S,
    2. Ham B-J,
    3. Pyun S-B,
    4. Kang S-H,
    5. Kim B-J
    . Current clinical applications of diffusion-tensor imaging in neurological disorders. J Clin Neurol 2018; 14: 129-140.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Giussani C,
    2. Poliakov A,
    3. Ferri RT,
    4. Plawner LL,
    5. Browd SR,
    6. Shaw DWW, et al.
    DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. NeuroImage 2010; 52: 217-123.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Kolakshyapati M,
    2. Hashizume A,
    3. Ochi K,
    4. Ueno H,
    5. Kaichi Y,
    6. Takayasu T, et al.
    Usefulness of histogram-profile analysis in ring-enhancing intracranial lesions. World Neurosurg 2019; 131: e226-e236.
    OpenUrl
  37. 37.↵
    1. Soni N,
    2. Srindharan K,
    3. Kumar S,
    4. Mishra P,
    5. Bathla G,
    6. Jyantee Kalita J, et al.
    Arterial spin labeling perfusion: Prospective MR imaging in differentiating neoplastic from non-neoplastic intra-axial brain lesions. Neuroradiol J 2018; 31: 544-553.
    OpenUrl
  38. 38.↵
    1. Bauckneht M,
    2. Capitanio S,
    3. Raffa S,
    4. Roccatagliata L,
    5. Pardini M,
    6. Lapucci C, et al.
    Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. EJNMMI Radiopharm Chem 2019; 4: 6.
    OpenUrl
  39. 39.↵
    1. Palanichamy K,
    2. Chakravarti A
    . Diagnostic and prognostic significance of methionine uptake and methionine positron emission tomography imaging in gliomas. Front Oncol 2017; 7: 257.
    OpenUrl
  40. 40.↵
    1. Yasuda S,
    2. Yano H,
    3. Kimura A,
    4. Suzui N,
    5. Nakayama N,
    6. Shinoda J, et al.
    Frontal tumefactive demyelinating lesion mimicking glioblastoma differentiated by methionine positron emission tomography. World Neurosurg 2018; 119: 244-248.
    OpenUrl
  41. 41.↵
    1. Hashimoto S,
    2. Inaji M,
    3. Nariai T,
    4. Kobayashi D,
    5. Sanjo N,
    6. Yokota T, et al.
    Usefulness of [11C] methionine PET in the differentiation of tumefactive multiple sclerosis from high grade astrocytoma. Neurol Med Chir (Tokyo) 2019; 59: 176-183.
    OpenUrl
  42. 42.↵
    1. Ikeguchi R,
    2. Shimizu Y,
    3. Abe K,
    4. Shimizu S,
    5. Maruyama T,
    6. Nitta M, et al.
    Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas. Mult Scler Relat Disord 2018; 26: 77-84.
    OpenUrl
  43. 43.↵
    1. Ikeguchi R,
    2. Shimizu Y,
    3. Shimizu S,
    4. Kitagawa K
    . CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma. Mult Scler 2018; 24: 1212-1223.
    OpenUrl
  44. 44.↵
    1. Abdullah S,
    2. Wong WF,
    3. Tan CT
    . The prevalence of anti-aquaporin 4 antibody in patients with idiopathic inflammatory demyelinating diseases presented to a tertiary hospital in Malaysia: Presentation and prognosis. Mult Scler Int 2017; 2017: 1359761.
    OpenUrl
  45. 45.↵
    1. Ongphichetmetha T,
    2. Aungsumart S,
    3. Siritho S,
    4. Metha P,
    5. Jantima T,
    6. Natthapon R, et al.
    Tumefactive demyelinating lesions: a retrospective cohort study in Thailand. Sci Rep 2024; 14: 1426.
    OpenUrl
  46. 46.↵
    1. Codjia P,
    2. Ayrignac X,
    3. Carra-Dalliere C,
    4. Cohen M,
    5. Charif M,
    6. Lippi A, et al.
    Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. Mult Scler Relat Disord 2019; 28: 109-116.
    OpenUrl
  47. 47.↵
    1. Wingerchuk DM,
    2. Banwell B,
    3. Bennett JL,
    4. Cabre P,
    5. Carroll W,
    6. Chitnis T, et al.
    International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Miyaue N,
    2. Yamanishi Y,
    3. Tada S,
    4. Ando R,
    5. Yabe H,
    6. Nagai M, et al.
    A case of ADEM-like presentation with anti-MOG antibody following tumefactive demyelinating lesion. Mult Scler Relat Disord 2019; 31: 62-64.
    OpenUrl
  49. 49.↵
    1. Pradhan S,
    2. Choudhury SS,
    3. Das A
    . Tumefactive acute disseminated encephalomyelitis. Neurol India 2017; 65: 558-560.
    OpenUrl
  50. 50.↵
    1. Hardy TA
    . Pseudotumoral demyelinating lesions: diagnostic approach and long-term outcome. Curr Opin Neurol 2019; 32: 467–474.
    OpenUrlPubMed
  51. 51.↵
    1. Ripellino P,
    2. Khonsari R,
    3. Stecco A,
    4. Filippi M,
    5. Perchinunno M,
    6. Cantello R
    . Clues on Balò’s concentric sclerosis evolution from serial analysis of ADC values. Int J Neurosci 2014; 126: 1-15.
    OpenUrl
  52. 52.↵
    1. Darke M,
    2. Bahador FM,
    3. Miller DC,
    4. Litofsky NS,
    5. Ahsan H
    . Baló’s concentric sclerosis: imaging findings and pathological correlation. J Radiol Case Rep 2013; 7: 1-8.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Totaro R,
    2. Di Carmine C,
    3. Marini C,
    4. Carolei A
    . Tumefactive demyelinating lesions: spectrum of disease, diagnosis and treatment. Curr Neurobiol. 2016; 7: 21-26.
    OpenUrl
  54. 54.↵
    1. Altintas A,
    2. Petek B,
    3. Isik N,
    4. Terzi M,
    5. Bolukbasi F,
    6. Tavsanli M, et al.
    Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler 2012; 18: 1448-1453.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Magana S,
    2. Keegan B,
    3. Weinshenker B,
    4. Erickson BJ,
    5. Pittock SJ,
    6. Lennon VA, et al.
    Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011; 68: 870-878.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    1. Ikeda KM,
    2. Lee DH,
    3. Fraser JA,
    4. Mirsattari S,
    5. Morrow SA
    . Plasma exchange in a patient with tumefactive, corticosteroid-resistant multiple sclerosis. Int J MS Care 2015; 17: 231-235.
    OpenUrl
  57. 57.↵
    1. Keegan M,
    2. Pineda AA,
    3. McClelland RL,
    4. Darby CH,
    5. Rodriguez M,
    6. Weinshenker BG
    . Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58: 143-146.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Solomon AJ,
    2. Bourdette DN,
    3. Cross AH,
    4. Applebee A,
    5. Skidd PM,
    6. Howard DB, et al.
    The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology 2016; 87: 1393-1399.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section